RADX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

RADX ▲ +2.46% at T+20d

LONG call ✓ call won +2.46% · α vs SPY -6.09% · entry $4.48 → $4.59

Next anchor: T+60d in 23d

Currently $4.25 · -5.13% from $4.48 entry

Entry anchored
Apr 7, 03:59 PM ET
via Databento tick

T+1d

+4.24%

call +4.24% · α +3.67%

$4.67

settled 2mo ago

T+5d

+3.79%

call +3.79% · α +0.28%

$4.65

settled 8w ago

T+20d

+2.46%

call +2.46% · α -6.09%

$4.59

settled 5w ago

T+60d

—

call — · α —

—

in 23d

Price Chart

Loading chart...

Executive Summary

Radiopharm Theranostics announced a positive safety review by the Data Safety and Monitoring Committee, allowing advancement of its RAD202 Phase 1 'HEAT' trial to a higher dose level of 130mCi in HER2-positive solid tumors. This progress confirms the therapy's favorable safety profile and keeps the company on track to complete dose escalation by end-2026.

Actionable Insight

Traders should monitor upcoming clinical updates, particularly completion of Phase 1 dose escalation by end-2026. This safety milestone reduces near-term risk and supports potential for future value inflection on efficacy data. Given the company's small market cap ($55M), further clinical progress could drive outsized stock movement.

Key Facts

Radiopharm Theranostics advanced RAD202 to 130mCi dose level in Phase 1 'HEAT' trial for HER2-positive solid tumors.
Decision follows positive recommendation from Data Safety and Monitoring Committee (DSMC).
Prior dose level was 75mCi, announced October 1, 2025.
Phase 1 dose escalation expected to complete by end of 2026.
Trial ongoing in Australia with no reported safety concerns at current dose.

Financial Impact

Non-dilutive catalyst progression; no direct financial impact yet, but de-risks clinical pathway.

pipeline valuedevelopment riskinvestor sentiment

Risk Factors

Phase 1 safety success does not guarantee efficacy in later stages.
Next dose level (130mCi) may reveal new safety signals.
Low liquidity and OTC listing increase volatility risk.

Market Snapshot

Exchange

OTC

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3269961

2 reports for RADX

T+1T+5T+20T+60

Filters

Reports for RADX — sortable, filterable
	Type				Now
Apr 8, 2026 8w ago	Press Release BULLISH ★ 7/10	$4.48 $4.59	▲ +2.46%	▼ −6.09%	$4.25 (−5.13%)
Mar 27, 2026 10w ago	Press Release NEUTRAL ★ 5/10	$4.25 $4.65	▲ +9.41%	▼ −3.33%	$4.25 (0.00%)

US Market Status

Market Closed — Opens Thu (11h 12m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access